American Association for Cancer Research
Browse
can-22-1533_supplementary_figures_s1-s7_suppsfl1-sfl7.pdf (14.13 MB)

Supplementary Figures S1-S7 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

Download (14.13 MB)
journal contribution
posted on 2023-03-31, 06:01 authored by Jesse C. Patterson, Andreas Varkaris, Peter J.P. Croucher, Maya Ridinger, Susan Dalrymple, Mannan Nouri, Fang Xie, Shohreh Varmeh, Oliver Jonas, Matthew A. Whitman, Sen Chen, Saleh Rashed, Lovemore Makusha, Jun Luo, John T. Isaacs, Mark G. Erlander, David J. Einstein, Steven P. Balk, Michael B. Yaffe

Seven Supplementary Figures and Legends

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

National Institutes of Health (NIH)

Charles and Marjorie Holloway Foundation

Ovarian Cancer Research Fund (OCRF)

Prostate Cancer Foundation (PCF)

MIT Center for Precision Cancer Medicine

Koch Institute - Dana-Farber/Harvard Cancer Center Bridge Project Grant

American Cancer Society (ACS)

Janssen/TRANSCEND

National Institute of Environmental Health Sciences (NIEHS)

United States Department of Health and Human Services

Find out more...

History

ARTICLE ABSTRACT

Abiraterone is a standard treatment for metastatic castrate-resistant prostate cancer (mCRPC) that slows disease progression by abrogating androgen synthesis and antagonizing the androgen receptor (AR). Here we report that inhibitors of the mitotic regulator polo-like kinase-1 (Plk1), including the clinically active third-generation Plk1 inhibitor onvansertib, synergizes with abiraterone in vitro and in vivo to kill a subset of cancer cells from a wide variety of tumor types in an androgen-independent manner. Gene-expression analysis identified an AR-independent synergy-specific gene set signature upregulated upon abiraterone treatment that is dominated by pathways related to mitosis and the mitotic spindle. Abiraterone treatment alone caused defects in mitotic spindle orientation, failure of complete chromosome condensation, and improper cell division independently of its effects on AR signaling. These effects, although mild following abiraterone monotherapy, resulted in profound sensitization to the antimitotic effects of Plk1 inhibition, leading to spindle assembly checkpoint-dependent mitotic cancer cell death and entosis. In a murine patient-derived xenograft model of abiraterone-resistant metastatic castration-resistant prostate cancer (mCRPC), combined onvansertib and abiraterone resulted in enhanced mitotic arrest and dramatic inhibition of tumor cell growth compared with either agent alone. Overall, this work establishes a mechanistic basis for the phase II clinical trial (NCT03414034) testing combined onvansertib and abiraterone in mCRPC patients and indicates this combination may have broad utility for cancer treatment. Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types.

Usage metrics

    Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC